Weight Loss Breakthrough: Higher Semaglutide Dose Delivers Astonishing 21% Reduction
- A higher 7.2 mg dose of semaglutide resulted in a remarkable average body weight loss of 21% in adults with obesity6.
- A staggering one-third of participants taking the higher dose shed 25% or more of their body weight, setting a new benchmark1, 5.
- The powerful new dose maintains a safety profile consistent with existing semaglutide treatments, paving the way for a new therapeutic option4.
The landscape of obesity treatment has been rocked by another seismic shift. Groundbreaking data from the STEP UP trial, presented at the American Diabetes Association (ADA) Scientific Sessions, reveals that a higher dose of semaglutide is pushing the boundaries of what's possible in medical weight management.
The trial demonstrated that a 7.2 mg dose of semaglutide achieved an average weight loss of 21% over 72 weeks—a figure that dramatically outshines the 3.9% seen in the placebo group6. This isn't just incremental progress; it's a leap forward. The most stunning revelation is the sheer magnitude of the transformation for many: a full third of individuals on the higher dose lost at least a quarter of their total body weight, a result previously unimaginable for many patients1, 5.
Crucially, this unprecedented efficacy does not come at the expense of safety. The trial confirmed a well-tolerated profile consistent with the established GLP-1 drug class. The most common adverse events were mild-to-moderate gastrointestinal issues that typically subsided over time, with a very low discontinuation rate4. These findings signal a new era in the fight against obesity, offering a potent new tool for patients and clinicians striving to achieve profound, life-changing health outcomes3.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.